UnknownPhase 2ketamine

Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population

Sponsored by Paul J. Lamothe

NCT ID
NCT01868802
Target Enrollment
60 participants
Start Date
2013-09

About This Study

A randomized multicentric parallel arms study involving the use of ketamine for treatment-resistant depression will be held at three national health provider clinics in the Mexican population. The purpose of this study is to determine whether clinical response seen in previous studies is replicable in this population.

Conditions Studied

Depressive Disorder,Treatment-Resistant Depression

Interventions

  • Ketamine
  • Placebo

Eligibility

Age:18 Years - 65 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

* Age: 18-65 years old
* Mayor Depressive Disorder Diagnosis based on DSM-IV TR.
* Classification of MDD as treatment-resistant.
* No brain structural abnormalities as evidenced by an MRI scan.
* Signed acceptance of Informed Consent.

Exclusion Criteria:

* Other psychiatric diagnosis apart from MDD.
* Substance abuse or dependence (prior or during study).
* Pregnancy.
* Congestive heart disease.
* Personal history of psychosis.
* First-degree relative with history of psychosis.
* Glaucoma.
* Present neurological disease.
* High blood or pulmonary artery pressure.
* Declining the signing of the informed consent.

Study Locations (1)

ABC Neurological Center
Mexico City, Mexico City, Mexico

This trial is not recruiting

This study is currently not accepting new participants.

Find recruiting trials
Data Source
ClinicalTrials.gov

Last updated from source

Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population | Huxley